Not disagreeing with your general point, but this statement is not accurate. For example, cross-reactive antibodies from other common cold coronaviruses can provide immune protection [1], which may partially explain why a large fraction of people are completely asymptomatic after initial SARS-COV-2 infection.
> COVID-19 patients elicit strong responses to the nucleocapsid (N) protein of SARS-CoV-2 but binding antibodies are also detected in prepandemic individuals, indicating potential crossreactivity with common cold human coronaviruses (HCoV) [1]
> In our study, we speculate that preexisting OC43 HCoV IgGs to N protein could be protective and, as a result, incoming SARS-CoV-2 infections would be more controlled and thus fewer antibodies induced against them.
> In conclusion, N protein is a primary target of SARS-CoV-2-specific and HCoV crossreactive antibodies, both of which may affect the acquisition of immunity to COVID-19. [1]
[1] Immunogenicity and crossreactivity of antibodies to the nucleocapsid protein of SARS-CoV-2: utility and limitations in seroprevalence and immunity studies https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7879156/